规范服用双联抗血小板药物对PCI术后冠心病患者预后的影响

被引：11

作者：

汪哲

张建华

徐岩

伍梦佐

陈旭华

陈斌

程自平

机构：

[1] 安徽医科大学第一附属医院心内科

来源：

临床心血管病杂志 | 2014年 / 30卷 / 03期

关键词：

抗血小板治疗; 经皮冠状动脉介入治疗术; 初级终点事件;

D O I：

10.13201/j.issn.1001-1439.2014.03.010

中图分类号：

R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）];

学科分类号：

摘要：

目的:探讨规范服用双联抗血小板药物对经皮冠状动脉介入治疗术(PCI)后冠心病患者预后的影响。方法:选取2008-2012年在安徽医科大学第一附属医院被确诊为冠心病并行PCI的患者489例进行随访,通过COX回归方法分析规范服用双联抗血小板药物对初级终点事件(全因死亡,非致死性脑卒中及非致死性心肌梗死)及次级终点事件(Ⅳ级心功能及再血管化治疗)的影响。结果:规范服药组初级终点事件的发生率低于非规范服药组(5%∶17%,P<0.001),两组间差异有统计学意义;而次级终点事件规范用药组发生率低于非规范用药组,但两组间无统计学差异。COX回归分析发现规范服用双联抗血小板药物可减少冠心病患者初级终点事件的发生率(RR=0.315,95%CI:0.150～0.666,P=0.002),但对次级终点事件无预测价值。进一步分析显示规范服用抗血小板药物仅对卒中发生的减少有统计学意义(RR=0.085,95%CI:0.020～0.366,P=0.001),对全因死亡及非致死性心肌梗死的发生无预测价值。结论:规范服用双联抗血小板药物可减少初级终点事件,特别是卒中的发生。

引用

页码：211 / 214

页数：4

共 13 条

[1] Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. Steinhubl S R,Berger P B,Mann J T 3rd,et al. The Journal of The American Medical Association . 2002
[2] Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation. DBA Eric L. Eisenstein,PhD Kevin J. Anstrom,MD David F. Kong,MS Linda K. Shaw,MSPH Robert H. Tuttle,MD Daniel B. Mark,MD Judith M. Kramer,MD Robert A. Harrington,MD David B. Matchar,MD David E. Kandzari,MD Eric D. Peterson,MD Kevin A. Schulman. The Journal of The American Medical Association . 2007
[3] Benefit of Long-Term Dual Anti-Platelet Therapy in Patients Treated With Drug-Eluting Stents: From the NHLBI Dynamic Registry[J] . Suresh R. Mulukutla,Oscar C. Marroquin,Helen A. Vlachos,Faith Selzer,Catalin Toma,Kevin E. Kip,J. Dawn Abbott,Elizabeth Holper,Joon S. Lee,Sameer Khandhar,Michael Kutcher,Sheryl Kelsey,Conrad Smith,David Faxon,David O. Williams. &nbspThe American Journal of Cardiology . 2013
[4] Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study[J] . Shamir R Mehta,Salim Yusuf,Ron JG Peters,Michel E Bertrand,Basil S Lewis,Madhu K Natarajan,Klas Malmberg,Hans-Jürgen Rupprecht,Feng Zhao,Susan Chrolavicius,Ingrid Copland,Keith AA Fox. &nbspThe Lancet . 2001 (9281)
[5] Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. Germano Di Sciascio,Giuseppe Patti,Vincenzo Pasceri,Giuseppe Colonna,Fabio Mangiacapra,Antonio Montinaro,on behalf of the ARMYDA-4 RELOAD Investigato. European Heart Journal . 2010
[6] 2011美国经皮冠状动脉介入治疗指南解读
吕树铮
汪国忠
[J]. 中国医学前沿杂志(电子版), 2012, 4 (06) : 41 - 48
[7] Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. CINDY L,ROBERT O,DONALD E,et al. The Journal of The American Dental Association . 2007
[8] 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention[J] . Glenn N. Levine,Eric R. Bates,James C. Blankenship,Steven R. Bailey,John A. Bittl,Bojan Cercek,Charles E. Chambers,Stephen G. Ellis,Robert A. Guyton,Steven M. Hollenberg,Umesh N. Khot,Richard A. Lange,Laura Mauri,Roxana Mehran,Issam D. Moussa,Debabrata Mukherjee,Brahmajee K. Nallamothu,Henry H. Ting. &nbspJournal of the American College of Cardiology . 2011 (24)
[9] Effectiveness of Two-Year Clopidogrel + Aspirin in Abolishing the Risk of Very Late Thrombosis After Drug-Eluting Stent Implantation (from the TYCOON [Two-Year ClOpidOgrel Need] Study)[J] . Gaetano Tanzilli,Cesare Greco,Francesco Pelliccia,Vincenzo Pasceri,Francesco Barillà,Vincenzo Paravati,Gaetano Pannitteri,Carlo Gaudio,Enrico Mangieri. &nbspThe American Journal of Cardiology . 2009 (10)
[10] Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting: A Randomized Multicenter Trial[J] . &nbspCirculation . 2012 (16)

← 1 2 →